Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Acrivon Therapeutics Inc (ACRV)

Acrivon Therapeutics Inc (ACRV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 205,770
  • Shares Outstanding, K 22,637
  • Annual Sales, $ 0 K
  • Annual Income, $ -60,390 K
  • 60-Month Beta 1.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.57
Trade ACRV with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.89
  • Number of Estimates 5
  • High Estimate -0.69
  • Low Estimate -0.97
  • Prior Year -0.58
  • Growth Rate Est. (year over year) -53.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.70 +44.39%
on 04/08/24
11.90 -30.84%
on 04/09/24
+0.98 (+13.52%)
since 04/01/24
3-Month
3.19 +157.99%
on 02/13/24
11.90 -30.84%
on 04/09/24
+4.37 (+113.21%)
since 02/01/24
52-Week
3.19 +157.99%
on 02/13/24
14.30 -42.45%
on 05/16/23
-4.19 (-33.74%)
since 05/01/23

Most Recent Stories

More News
Catalyst (CPRX) to Report Q1 Earnings: What's in the Cards?

Catalyst's (CPRX) revenues in the first quarter of 2023 are expected to have been driven by Firdapse sales. Updates on generic competition and the commercial launch of Fycompa are expected.

IMGN : 31.23 (unch)
CYT : 3.02 (-2.27%)
CPRX : 15.20 (+1.00%)
ACRV : 8.23 (-9.46%)
2 Breakout Growth Stocks to Buy for the Long Haul

These two healthcare stocks have crushed the broader markets this year.

ACRV : 8.23 (-9.46%)
VRCA : 6.85 (-1.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Acrivon Therapeutics Inc. is a clinical stage biopharmaceutical company developing precision oncology medicines which matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon's proprietary proteomics-based patient responder identification platform,...

See More

Key Turning Points

3rd Resistance Point 10.30
2nd Resistance Point 9.83
1st Resistance Point 9.03
Last Price 8.23
1st Support Level 7.76
2nd Support Level 7.29
3rd Support Level 6.49

See More

52-Week High 14.30
Fibonacci 61.8% 10.06
Fibonacci 50% 8.74
Last Price 8.23
Fibonacci 38.2% 7.43
52-Week Low 3.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar